Signup/Login
If you want to receive notifications of upcoming IPOs, you need to simply sign up or sign in with social networks.
Signup/Login
Can you determine which companies are good and which ones - the trash?
Free Pro-version
IPO Filter
Monitor
IPO today
Forest Road Acquisition (FRX.U)
Upcoming IPO
Lixte Biotechnology Holdings (LIXT)
Seaport Global Acquisition (SGAMU)
Spartan Acquisition Corp. II (SPRQ.U)
AMMO (POWW)
Priced IPO
HF Enterprises (HFEN)
Vision Marine Technologies (VMAR)
Ozon Holdings Plc (OZON)
Sotera Health Company (SHC)
Maravai LifeSciences Holdings, Inc. (MRVI)
Telos Corporation (TLS)
NeoGames S.A (NGMS)
Olema Pharmaceuticals, Inc. (OLMA)
Yatsen Holding Limited (YSG)
Lufax Holding Ltd (LU)
Atea Pharmaceuticals, Inc. (AVIR)
SQZ Biotechnologies Company (SQZ)
Allegro MicroSystems, Inc. (ALGM)
Galecto, Inc. (GLTO)
Leslie's Inc (LESL)
Gatos Silver, Inc. (GATO)
Biodesix, Inc. (BDSX)
MediaAlpha, Inc. (MAX)
Root, Inc. (ROOT)
Absolute Software (ABST)
More companies

Aligos Therapeutics, Inc (ALGS)

Sector - Healthcare

Price chart

Company News

IPO Profile

About company

They are a clinical-stage biopharmaceutical company currently focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases. They utilize their proprietary oligonucleotide and small molecule platforms to develop pharmacologically optimized drug candidates for use in combination regimens designed to achieve improved treatment outcomes. Their lead effort is to develop a functional cure for Chronic Hepatitis B (CHB), which often results in other life-threatening conditions such as cirrhosis, end-stage liver disease (ESLD) and the most common form of liver cancer, hepatocellular carcinoma (HCC). The most widely used treatment for CHB, nucleos(t)ide analogs, suppresses viral replication but only achieves low rates of functional cure and often requires long-term administration. To address this issue, they have developed a portfolio of differentiated drug candidates for CHB, including an S-antigen Transport-inhibiting Oligonucleotide Polymers (STOPS) molecule, a small molecule Capsid Assembly Modulator (CAM), and oligonucleotides (ASO and siRNA), each of which is designed against clinically validated targets in the Hepatitis B Virus (HBV) life cycle. They believe that combination regimens utilizing their portfolio of CHB drug candidates may lead to higher rates of functional cure. A Phase 1 proof of concept trial for their STOPS molecule is ongoing in New Zealand and they expect to initiate a Phase 1 clinical trial with their CAM in the second half of 2020.
Industry
BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)
CEO CFO
Lawrence M. Blatt Lesley Ann Calhoun
Employees Founded
67 2018

Contacts

Address: One Corporate Dr., 2nd Floor South San Francisco, CA 94080

Telephone: (800) 466-6059

Web page: http://www.aligos.com

IPO information

Expected Date 10/16/2020
Status Priced
Exchange NASDAQ
Lockup Period Expiration .Pro
Quiet Period Expiration .Pro
Old Price Range
-
Share prices ($)

Financial Data (last reporting year)

Market Cap (MM) $507.0
Revenues (MM) $0
Net Income (Loss) (MM) $-73.1

Voting

What do you think will happen with the ALGS share price after the next 3-6 months? 🔥 (+ 10% or more, flat (+ -10%), -10% or less)

Number of votes: img
Shares Initial (MM) 10
Shares Revised (MM) -
Expected offer amount (MM) $150
Realized offer amount(MM) $0
Underwriters
JP Morgan/ Jefferies/ Piper Sandler
CO-Managers
Cantor

Sector: Healthcare

Tweets about $ALGS

Tweets volume:

RT volume:

Timeframe:

Google Trends Stats